Reason for request
Reassessment
Summary of opinion
Favourable opinion for reimbursement in the treatment of HIV-1 infection only in adults and adolescents above 12 years of age weighing at least 40 kg:
- who are treatment-naive, with a CD4 count of more than 200/mm3, a viral load (VL) of less than 500,000 copies/mL and with no known or suspected resistance to either of the two drugs;
- previously treated, with a stable VL < 50 copies/mL for at least one year, a CD4 count of more than 350/mm3 and with no known or suspected resistance to either of the two drugs.
Unfavourable opinion for reimbursement in the other situations covered by the MA indication.
Clinical Benefit
| Substantial |
The clinical benefit of DOVATO (dolutegravir/lamivudine) is substantial only in adults and adolescents above 12 years of age
weighing at least 40 kg:
- who are treatment-naive, with a CD4 count of more than 200/mm3, a viral load (VL) of less than 500,000 copies/mL and with no known or suspected resistance to either of the two drugs;
- previously treated, with a stable VL < 50 copies/mL for at least one year, a CD4 count of more than 350/mm3 and with no known or suspected resistance to either of the two drugs.
|
| Insufficient |
The clinical benefit is insufficient to justify public funding cover in the other populations of the MA. |
Clinical Added Value
| minor |
Updating of the reimbursement scope in view of the long-term follow-up data from the GEMINI 1 and 2 studies and in line with current HAS recommendations, does not modify the clinical added value level of DOVATO (dolutegravir/lamivudine) according to the opinion of 8 January 2020:
- minor clinical added value (CAV IV) in the treatment of HIV-1 infection in adults and adolescents above 12 years of age who are treatment-naive, with a CD4 count of more than 200/mm3, a VL of < 500,000 copies/mL and with no known or suspected resistance to either of the two drugs,
- no clinical added value (CAV V) in the treatment of patients infected with HIV-1, who are previously treated and virologically suppressed, compared to the proprietary medicinal product JULUCA.
|
| no clinical added value |
Updating of the reimbursement scope in view of the long-term follow-up data from the GEMINI 1 and 2 studies and in line with current HAS recommendations, does not modify the clinical added value level of DOVATO (dolutegravir/lamivudine) according to the opinion of 8 January 2020:
- minor clinical added value (CAV IV) in the treatment of HIV-1 infection in adults and adolescents above 12 years of age who are treatment-naive, with a CD4 count of more than 200/mm3, a VL of < 500,000 copies/mL and with no known or suspected resistance to either of the two drugs,
- no clinical added value (CAV V) in the treatment of patients infected with HIV-1, who are previously treated and virologically suppressed, compared to the proprietary medicinal product JULUCA.
|
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
cSXnmuwTRAPFdnr8
